BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38563164)

  • 21. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
    Reardon DA; Vredenburgh JJ; Desjardins A; Peters K; Gururangan S; Sampson JH; Marcello J; Herndon JE; McLendon RE; Janney D; Friedman AH; Bigner DD; Friedman HS
    J Neurooncol; 2011 Jan; 101(1):57-66. PubMed ID: 20443129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
    Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
    Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage.
    Mehta M; Griffith J; Panneerselvam J; Babu A; Mani J; Herman T; Ramesh R; Munshi A
    Int J Radiat Biol; 2021; 97(8):1109-1120. PubMed ID: 32052681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of cellular, molecular and tumor microenvironment in hepatocellular carcinoma: Possible targets and future directions in the regorafenib era.
    Juengpanich S; Topatana W; Lu C; Staiculescu D; Li S; Cao J; Lin J; Hu J; Chen M; Chen J; Cai X
    Int J Cancer; 2020 Oct; 147(7):1778-1792. PubMed ID: 32162677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regorafenib Reverses Temozolomide-Induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma.
    Chiang IT; Liu YC; Liu HS; Ali AAA; Chou SY; Hsu TI; Hsu FT
    Neurotherapeutics; 2022 Mar; 19(2):616-634. PubMed ID: 35267171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report.
    Yoshino K; Manaka D; Kudo R; Kanai S; Mitsuoka E; Kanto S; Hamasu S; Konishi S; Nishitai R
    J Med Case Rep; 2017 Aug; 11(1):227. PubMed ID: 28818109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Observational real-life study on regorafenib in recurrent glioblastoma: does dose reduction reduce toxicity while maintaining the efficacy?
    Rudà R; Bruno F; Pellerino A; Pronello E; Palmiero R; Bertero L; Crasto S; Polo V; Vitaliani R; Trincia E; Internò V; Porta C; Soffietti R
    J Neurooncol; 2022 Nov; 160(2):389-402. PubMed ID: 36309895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regorafenib (BAY 73-4506): stromal and oncogenic multikinase inhibitor with potential activity in renal cell carcinoma.
    Zaki K; Aslam S; Eisen T
    Curr Oncol Rep; 2013 Apr; 15(2):91-7. PubMed ID: 23334510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regorafenib as treatment for patients with advanced hepatocellular cancer.
    Thillai K; Srikandarajah K; Ross P
    Future Oncol; 2017 Oct; 13(25):2223-2232. PubMed ID: 28766967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regorafenib: A Review in Hepatocellular Carcinoma.
    Heo YA; Syed YY
    Drugs; 2018 Jun; 78(9):951-958. PubMed ID: 29915898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Grothey A; Van Cutsem E; Sobrero A; Siena S; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Tabernero J; Yoshino T; Lenz HJ; Goldberg RM; Sargent DJ; Cihon F; Cupit L; Wagner A; Laurent D;
    Lancet; 2013 Jan; 381(9863):303-12. PubMed ID: 23177514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial).
    Lombardi G; Del Bianco P; Brandes AA; Eoli M; Rudà R; Ibrahim T; Lolli I; Rizzato S; Daniele B; Pace A; Pasqualetti F; Caccesse M; Bergo E; Magni G; De Salvo GL; Zagonel V
    Eur J Cancer; 2021 Sep; 155():179-190. PubMed ID: 34388515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.
    Belum VR; Wu S; Lacouture ME
    Invest New Drugs; 2013 Aug; 31(4):1078-86. PubMed ID: 23700287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK.
    Lau DK; Luk IY; Jenkins LJ; Martin A; Williams DS; Schoffer KL; Chionh F; Buchert M; Sjoquist K; Boussioutas A; Hayes SA; Ernst M; Weickhardt AJ; Pavlakis N; Tebbutt NC; Mariadason JM
    Mol Cancer Ther; 2021 Apr; 20(4):704-715. PubMed ID: 33563752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regorafenib for treatment of advanced gastrointestinal stromal tumors.
    Overton LC; Heinrich MC
    Expert Opin Pharmacother; 2014 Mar; 15(4):549-58. PubMed ID: 24405315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regorafenib induces lethal autophagy arrest by stabilizing PSAT1 in glioblastoma.
    Jiang J; Zhang L; Chen H; Lei Y; Zhang T; Wang Y; Jin P; Lan J; Zhou L; Huang Z; Li B; Liu Y; Gao W; Xie K; Zhou L; Nice EC; Peng Y; Cao Y; Wei Y; Wang K; Huang C
    Autophagy; 2020 Jan; 16(1):106-122. PubMed ID: 30909789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.
    Mross K; Frost A; Steinbild S; Hedbom S; Büchert M; Fasol U; Unger C; Krätzschmar J; Heinig R; Boix O; Christensen O
    Clin Cancer Res; 2012 May; 18(9):2658-67. PubMed ID: 22421192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
    Strumberg D
    Drugs Today (Barc); 2005 Dec; 41(12):773-84. PubMed ID: 16474853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma.
    Solms A; Reinecke I; Fiala-Buskies S; Keunecke A; Drenth HJ; Bruix J; Meinhardt G; Cleton A; Ploeger B
    Eur J Pharm Sci; 2017 Nov; 109S():S149-S153. PubMed ID: 28549676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.